DATA GRAPHICS | Discovery & Translation
Modalities, not targets, drive translational innovation at ASCO23
BioCentury’s analysis of first-in-human studies at ASCO 2023
June 8, 2023 10:06 PM UTC
Small molecules are down, new modalities are up, and immuno-oncology therapies are driving innovation, according to first-in-human studies presented at this year’s ASCO conference. Leading the charge were biotechs from North America and China.
BioCentury’s analysis of the nearly 6,000 abstracts presented during the 2023 American Society of Clinical Oncology annual meeting identified 75 first-in-human trials that had not previously reported data...
BCIQ Company Profiles